SCHEMBL9710697

SCHEMBL9710697

Cc1nc(C(N)=O)cn1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.36
MAP3K14 Q99558 1/20 0.35
CCNC P24863 2/20 0.35
CDK8 P49336 2/20 0.35
PLA2G10 O15496 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
GRM5 P41594 1/20 0.34
GRM2 Q14416 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
NNMT P40261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7489316 0.81 RXFP1 (0.42) BRD4KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL8812476 0.81 SMN1; SMN2 (0.35) BRD4POLBALDH1A1L3MBTL1KMT2A
SCHEMBL7575790 0.79 LMNA (0.38) BRD4LMNAPOLBCDK8PLA2G10
Hydrochloric Acid SCHEMBL31555571 0.79 RXFP1 (0.41) BRD4KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL28500403 0.79 P2RX7 (0.47) POLBKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL12321716 0.75 CDK8 (0.36) BRD4LMNAMAP3K14CCNCCDK8
SCHEMBL15474118 0.75 LMNA (0.38) BRD4LMNACCNCCDK8ADORA2A
SCHEMBL14297401 0.75 LMNA (0.34) BRD4LMNACCNCCDK8ADORA2A
SCHEMBL13734944 0.74 BRD4 (0.39) BRD4GRM5GRM2
SCHEMBL20713614 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102925136-A Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2013-02-13 CN claimed
WO-1992020674-A1 1H-IMIDAZOL-1-YL-METHYL BENZOFURAN DERIVATIVES, WITH THE IMIDAZOLYL MOIETY BEING SUBSTITUTED BY A CYCLOALKYL GROUP GLAXO GROUP LIMITED (GB) 1992-11-26 WO claimed
WO-2025080653-A1 PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUNDS ACTING AGAINST CANCERS, INFLAMMATORY DISEASES, AND FIBROTIC DISEASE VIA INTERACTION WITH RAS SUPERFAMILY PROTEINS SHY THERAPEUTICS, LLC (US) 2025-04-17 WO disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
WO-2024077391-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIVERSITE DE MONTREAL (CA) 2024-04-18 WO disclosed
WO-2021215545-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-10-28 WO disclosed
WO-2021019514-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2021-02-04 WO disclosed
CN-106061963-B Heterocyclic modulators of lipid synthesis and combinations thereof 3-V生物科学股份有限公司 2019-10-22 CN disclosed
US-20160168170-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 US disclosed
US-9303046-B2 Process for the preparation of heterocyclic ester derivatives JANSSEN PHARMACEUTICA NV (BE) 2016-04-05 US disclosed
WO-2016001789-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF CANCER PFIZER INC. (US) 2016-01-07 WO disclosed
US-20140046072-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-02-13 US disclosed
CN-102925136-A Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof UNIV DALIAN 2013-02-13 CN disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed
WO-2008137027-A2 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION CCL11, LTC4S, TSLP BRD4 370/4885LMNA 4658/4885POLB 3932/4885
US-20160168170-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES FLT3, FES, FLT1 BRD4 2063/4885LMNA 1252/4885POLB 3627/4885
US-20140046072-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES FLT3, FES, FLT1 BRD4 2063/4885LMNA 1252/4885POLB 3627/4885
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, BRAF, KRAS BRD4 596/4885LMNA 3697/4885POLB 113/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD BRD4 465/4885LMNA 2678/4885POLB 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.